Story

Intuitive Surgical Upgraded by Oppenheimer on Strategy to 'Crowd Out' U.S. Rivals

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Intuitive Surgical Upgraded by Oppenheimer on Strategy to 'Crowd Out' U.S. Rivals
Text size
Background

Oppenheimer has upgraded its rating on Intuitive Surgical (NASDAQ: ISRG) to Outperform from Perform, establishing a new price target of $500 per share. The investment firm's note on Wednesday cited the robotic surgery leader's effective strategy of "crowding out" domestic competition as a key driver for its more bullish stance.

Analyst's Thesis: Sidelining Competitors

Analyst Suraj Kalia stated the upgrade reflects "a more nuanced risk-reward assessment at these levels," according to the note. Oppenheimer's central argument is that Intuitive's business tactics, including its use of operating leases and customized price-volume contracts, make it financially punitive for U.S. rivals to gain market share.

The firm also highlighted that Intuitive's per-click business model provides significant flexibility, aiding its penetration into more price-sensitive, lower-acuity settings like Ambulatory Surgery Centers (ASCs).

U.S. Competitive Landscape

Oppenheimer characterized U.S. competition as a "non-factor" for Intuitive Surgical at present. The firm's field checks reportedly uncovered significant operational and logistical hurdles for competing systems.

Sample IUX Markets – In-articleAd
  • Johnson & Johnson's Ottava: Oppenheimer's checks flagged "unique workflow challenges" for the Ottava platform, specifically related to arm deployment in a non-sterile environment. The note also pointed to limited production capacity, projecting just 20 systems in 2026 and 100 in 2027.
  • Hugo System: The competing platform from Medtronic was said to face "real-estate issues," limiting its appeal.

International Headwinds and Market Growth

While confident in Intuitive's domestic dominance, the note was more cautious about the international landscape, where the company generates about 34% of its sales. Oppenheimer identified homegrown Chinese platforms—specifically Medbot, Kangduo, and Toumai—as "the biggest threats from a pricing/market share perspective."

Looking at the broader market, Oppenheimer forecasts the total robotic surgery market will grow to approximately 5.5 million procedures by 2030. This expanding market provides a significant backdrop for the ongoing competitive dynamics in the sector.

Read next

More on Stocks
Back to latest news

LATEST